Shuheng Zhang1, Jiwei Bai2, Mingxuan Li3, Yixuan Zhai4, Shuai Wang3, Qian Liu3, Chuzhong Li3, Songbai Gui5, Yazhuo Zhang6. 1. Beijing Neurosurgical Institute, Capital Medical University, Beijing, China; Department of Neurosurgery, Anshan Central Hospital, Anshan, China. 2. Beijing Neurosurgical Institute, Capital Medical University, Beijing, China; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. 3. Beijing Neurosurgical Institute, Capital Medical University, Beijing, China. 4. Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 5. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. 6. Beijing Neurosurgical Institute, Capital Medical University, Beijing, China; Department of Neurosurgery, Anshan Central Hospital, Anshan, China; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Electronic address: zyz2004520@yeah.net.
Abstract
OBJECTIVE: We aimed to characterize the expression of transforming growth factor-α (TGF-α) and Ki-67 and to assess the relationship between TGF-α and Ki-67 expression and prognostic factors in skull base chordoma. METHODS: We retrospectively analyzed the data from 46 patients with skull base chordoma. The follow-up duration ranged from 1 to 168 months (mean, 74.1). The survival data were statistically analyzed using the Kaplan-Meier method and multivariate Cox regression analysis. The expression of TGF-α and Ki-67 were detected by immunohistochemical staining of paraffin-embedded patient tissue specimens. RESULTS: The total resection (TR) group had longer overall survival compared with the non-TR group (P = 0.042). The TR group also had longer progression-free survival (PFS) than did the non-TR group (P = 0.046). The group with a high Ki-67 labeling index (Ki-67LI) had shorter overall survival than did the group with a low Ki-67LI (P = 0.039). Also, the group with a high Ki-67LI had significantly shorter PFS than did the group with a low Ki-67LI (P = 0.016). Moreover, the group with high TGF-α expression had significantly shorter PFS compared with the group with low TGF-α expression (P = 0.005). CONCLUSIONS: Our results have shown that high levels of TGF-α and Ki-67 are associated with shorter PFS in patients with chordoma. We have confirmed the role of Ki-67 as a functional molecular marker of poor prognosis. We also identified TGF-α as a potential novel biomarker for predicting prognosis for patients with skull base chordoma.
OBJECTIVE: We aimed to characterize the expression of transforming growth factor-α (TGF-α) and Ki-67 and to assess the relationship between TGF-α and Ki-67 expression and prognostic factors in skull base chordoma. METHODS: We retrospectively analyzed the data from 46 patients with skull base chordoma. The follow-up duration ranged from 1 to 168 months (mean, 74.1). The survival data were statistically analyzed using the Kaplan-Meier method and multivariate Cox regression analysis. The expression of TGF-α and Ki-67 were detected by immunohistochemical staining of paraffin-embedded patient tissue specimens. RESULTS: The total resection (TR) group had longer overall survival compared with the non-TR group (P = 0.042). The TR group also had longer progression-free survival (PFS) than did the non-TR group (P = 0.046). The group with a high Ki-67 labeling index (Ki-67LI) had shorter overall survival than did the group with a low Ki-67LI (P = 0.039). Also, the group with a high Ki-67LI had significantly shorter PFS than did the group with a low Ki-67LI (P = 0.016). Moreover, the group with high TGF-α expression had significantly shorter PFS compared with the group with low TGF-α expression (P = 0.005). CONCLUSIONS: Our results have shown that high levels of TGF-α and Ki-67 are associated with shorter PFS in patients with chordoma. We have confirmed the role of Ki-67 as a functional molecular marker of poor prognosis. We also identified TGF-α as a potential novel biomarker for predicting prognosis for patients with skull base chordoma.
Authors: J Bai; J Shi; S Zhang; C Zhang; Y Zhai; S Wang; M Li; C Li; P Zhao; S Geng; S Gui; L Jing; Y Zhang Journal: AJNR Am J Neuroradiol Date: 2020-05-07 Impact factor: 3.825
Authors: Franco Rubino; Christopher Alvarez-Breckenridge; Kadir Akdemir; Anthony P Conley; Andrew J Bishop; Wei-Lien Wang; Alexander J Lazar; Laurence D Rhines; Franco DeMonte; Shaan M Raza Journal: Front Oncol Date: 2022-09-29 Impact factor: 5.738